Summary of "More Exercise, More Plaque?"

Overview

This summary synthesizes key concepts, findings, and methods from multiple studies examining coronary artery plaque in endurance athletes, including recent work using wearable-monitor data. The core unexpected observation is that some groups of high-volume or highly trained endurance athletes have greater coronary plaque burden than less-trained but still active controls.

Main unexpected finding: several studies report that highly trained, high-volume endurance athletes can have greater coronary artery plaque burden than matched, less-trained active controls — in some analyses substantially higher — even when traditional risk factors are lower.

Key findings

Several cohorts of older, high-volume endurance athletes showed higher coronary plaque burden than less-trained active controls:
- A 2008 German study of 108 men over 50 who ran multiple marathons found higher calcified plaque versus matched non-marathon runners.
- Two 2017 papers in Circulation reported: elevated plaque in UK masters endurance athletes despite lower traditional risk factors; and 77% plaque prevalence in the highest weekly exercise-volume men (~age 55) versus 56% in the lowest-volume group.
- The 2023 Masters at Heart Consortium (Belgian) study found lifelong endurance athletes had more plaque; unlike earlier reports, their plaque was not consistently less risky (no clear shift toward safer, more-calcified plaques).
- A wearable-based study that used objective heart-rate and duration data found those with the highest training load (duration × heart-rate-derived intensity) were almost six times more likely to have plaque.
Plaque type and clinical risk:
- Two plaque phenotypes are emphasized:
  - Calcified plaque: generally more stable, less likely to rupture.
  - Non-calcified/soft plaque: less stable, higher rupture risk.
- Earlier studies sometimes suggested athletes’ plaques were more calcified (a possible “silver lining”); larger and more recent studies found no consistent reduction in risky plaque types among lifelong athletes.
- Importantly, across studies there is no consistent evidence that higher plaque burden in high-volume athletes translates into higher rates of heart attacks or cardiovascular mortality. For example, a large prospective cohort (n > 21,000) with ~17 years of follow-up found elevated plaque measures with high-volume exercise but no increase in deaths from heart disease or all-cause mortality.

Measurement and methodological insights

Many prior studies relied on self-reported exercise (recall questionnaires; MET-minutes calculated from intensity × time), which can be inaccurate and may obscure true associations.
The newer wearable-based study used objective heart-rate and duration monitoring to calculate training load (duration × heart-rate-derived intensity). Objective data revealed a strong association (high training load → more plaque) that largely disappeared when using conventional self-reported measures.
Most plaque assessments used CT coronary imaging. Several cohorts were screened to exclude standard cardiovascular risk factors in order to isolate potential effects of exercise exposure.

Interpretation about intensity versus volume

High intensity by itself (without large overall volume) was not associated with higher plaque in the wearable-based study.
High total volume showed stronger associations with plaque when that volume included substantial high-intensity training.
The combination of very high volume plus frequent high-intensity work appears most linked to greater plaque burden.

Practical and clinical implications

Exercise remains strongly protective for overall mortality and is the best-known intervention for longevity; these findings do not negate the benefits of physical activity.
Increased plaque burden in very active athletes does not necessarily indicate worse clinical outcomes based on current evidence.
Very fit people are not absolutely protected: highly active athletes can still develop plaque and should monitor traditional cardiovascular risk factors rather than assume immunity.
Measurement choice matters: wearables (objective monitoring) can change observed associations compared with self-report and improve study accuracy.
Some clinicians and individuals choose lipid-lowering therapies (e.g., statins, ezetimibe) for plaque reduction even in otherwise low-risk, active people. Decisions should be individualized and discussed with a treating physician.

Methodologies used (summary)

Matched-group comparison (2008): marathon runners vs matched non-runners with similar risk profiles; plaque assessed by CT.
Cross-sectional studies of masters/endurance athletes: CT imaging to compare plaque prevalence and phenotype across activity levels.
Wearable-based monitoring: continuous/regular heart-rate tracking plus session duration; training load calculated as duration × heart-rate-derived intensity; objective metrics compared with self-reported ones.
Large prospective cohort: observational follow-up (~17 years) of >21,000 participants examining plaque measures and long-term mortality outcomes.

Researchers and sources (as referenced)

2008 German research group (study of 108 marathon runners)
Two 2017 Circulation papers:
- UK masters endurance athletes (elevated plaque despite lower risk factors)
- Study of lifelong exercise volumes in active men (~age 55)
Masters at Heart Consortium (Belgian group) — 2023 comprehensive study and related papers
Recent wearable-based study (used heart-rate wearables to calculate training load; author names not provided in subtitles)
Large prospective cohort study (n > 21,000; ~17-year follow-up) reporting no increase in cardiovascular mortality despite higher plaque measures with high-volume exercise
PISE study (referenced in relation to LDL targets and clinical decision-making)

Note: Individual author names were not provided in the subtitle text; studies are listed by year/consortium as presented.